ScinoPharm Taiwan, Ltd. (1789.TW)
TWD 18.7
(-1.32%)
TWD 18.7
(-1.32%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.51 Billion TWD | 27.16% |
| 2022 | 1.18 Billion TWD | -11.62% |
| 2021 | 1.34 Billion TWD | 7.96% |
| 2020 | 1.24 Billion TWD | 10.81% |
| 2019 | 1.12 Billion TWD | -17.56% |
| 2018 | 1.36 Billion TWD | -18.58% |
| 2017 | 1.67 Billion TWD | -8.45% |
| 2016 | 1.82 Billion TWD | -15.65% |
| 2015 | 2.16 Billion TWD | -11.44% |
| 2014 | 2.44 Billion TWD | -2.51% |
| 2013 | 2.51 Billion TWD | 34.33% |
| 2012 | 1.87 Billion TWD | 27.62% |
| 2011 | 1.46 Billion TWD | 17.77% |
| 2010 | 1.24 Billion TWD | 31.25% |
| 2009 | 948.08 Million TWD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 1.66 Billion TWD | 10.31% |
| 2024 Q2 | 1.81 Billion TWD | 8.86% |
| 2023 Q1 | 1.4 Billion TWD | 18.07% |
| 2023 Q3 | 1.64 Billion TWD | 10.04% |
| 2023 Q4 | 1.51 Billion TWD | -7.98% |
| 2023 Q2 | 1.49 Billion TWD | 6.35% |
| 2023 FY | 1.51 Billion TWD | 27.16% |
| 2022 Q4 | 1.18 Billion TWD | -8.81% |
| 2022 Q2 | 1.26 Billion TWD | -2.55% |
| 2022 Q1 | 1.29 Billion TWD | -3.39% |
| 2022 FY | 1.18 Billion TWD | -11.62% |
| 2022 Q3 | 1.3 Billion TWD | 2.95% |
| 2021 Q2 | 1.44 Billion TWD | 1.82% |
| 2021 Q4 | 1.34 Billion TWD | -2.05% |
| 2021 Q1 | 1.42 Billion TWD | 14.2% |
| 2021 FY | 1.34 Billion TWD | 7.96% |
| 2021 Q3 | 1.37 Billion TWD | -5.21% |
| 2020 Q4 | 1.24 Billion TWD | -7.74% |
| 2020 Q2 | 1.29 Billion TWD | 1.83% |
| 2020 Q1 | 1.27 Billion TWD | 13.5% |
| 2020 FY | 1.24 Billion TWD | 10.81% |
| 2020 Q3 | 1.35 Billion TWD | 3.92% |
| 2019 Q3 | 1.23 Billion TWD | -4.34% |
| 2019 Q4 | 1.12 Billion TWD | -9.17% |
| 2019 Q2 | 1.29 Billion TWD | 3.19% |
| 2019 Q1 | 1.25 Billion TWD | -8.05% |
| 2019 FY | 1.12 Billion TWD | -17.56% |
| 2018 Q4 | 1.36 Billion TWD | -4.96% |
| 2018 FY | 1.36 Billion TWD | -18.58% |
| 2018 Q1 | 1.61 Billion TWD | -3.49% |
| 2018 Q2 | 1.51 Billion TWD | -6.19% |
| 2018 Q3 | 1.43 Billion TWD | -5.38% |
| 2017 Q1 | 1.94 Billion TWD | 6.09% |
| 2017 FY | 1.67 Billion TWD | -8.45% |
| 2017 Q4 | 1.67 Billion TWD | -8.46% |
| 2017 Q3 | 1.82 Billion TWD | 1.56% |
| 2017 Q2 | 1.8 Billion TWD | -7.18% |
| 2016 FY | 1.82 Billion TWD | -15.65% |
| 2016 Q3 | 2.01 Billion TWD | -2.13% |
| 2016 Q2 | 2.06 Billion TWD | -4.87% |
| 2016 Q1 | 2.16 Billion TWD | -0.08% |
| 2016 Q4 | 1.82 Billion TWD | -9.33% |
| 2015 Q1 | 2.4 Billion TWD | -1.91% |
| 2015 FY | 2.16 Billion TWD | -11.44% |
| 2015 Q4 | 2.16 Billion TWD | -5.22% |
| 2015 Q3 | 2.28 Billion TWD | -1.16% |
| 2015 Q2 | 2.31 Billion TWD | -3.62% |
| 2014 Q3 | 2.66 Billion TWD | -0.26% |
| 2014 Q4 | 2.44 Billion TWD | -8.21% |
| 2014 FY | 2.44 Billion TWD | -2.51% |
| 2014 Q2 | 2.67 Billion TWD | 1.46% |
| 2014 Q1 | 2.63 Billion TWD | 4.96% |
| 2013 Q3 | 2.35 Billion TWD | 3.1% |
| 2013 FY | 2.51 Billion TWD | 34.33% |
| 2013 Q1 | 2.22 Billion TWD | 19.01% |
| 2013 Q2 | 2.28 Billion TWD | 2.79% |
| 2013 Q4 | 2.51 Billion TWD | 6.51% |
| 2012 Q4 | 1.87 Billion TWD | -4.69% |
| 2012 FY | 1.87 Billion TWD | 27.62% |
| 2012 Q2 | 2.02 Billion TWD | 12.22% |
| 2012 Q1 | 1.8 Billion TWD | 22.94% |
| 2012 Q3 | 1.96 Billion TWD | -2.94% |
| 2011 Q3 | 1.4 Billion TWD | -0.02% |
| 2011 Q4 | 1.46 Billion TWD | 4.43% |
| 2011 Q2 | 1.4 Billion TWD | 0.0% |
| 2011 FY | 1.46 Billion TWD | 17.77% |
| 2010 FY | 1.24 Billion TWD | 31.25% |
| 2010 Q4 | 1.24 Billion TWD | 0.0% |
| 2009 FY | 948.08 Million TWD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Grape King Bio Ltd | 737.18 Million TWD | -105.041% |
| Standard Chem & Pharm CO., LTD. | 1.61 Billion TWD | 6.405% |
| Maywufa Company Ltd. | 257.91 Million TWD | -486.068% |
| Lotus Pharmaceutical Co., Ltd. | 3.77 Billion TWD | 59.963% |
| LIWANLI Innovation Co., Ltd. | 60.81 Million TWD | -2385.301% |
| YungShin Global Holding Corporation | 2.77 Billion TWD | 45.492% |
| PhytoHealth Corporation | 163.09 Million TWD | -826.81% |
| SCI Pharmtech, Inc. | 529.53 Million TWD | -185.447% |
| Formosa Laboratories, Inc. | 1.59 Billion TWD | 5.379% |
| PharmaEssentia Corporation | 1.45 Billion TWD | -3.626% |
| Bora Pharmaceuticals Co., LTD. | 2.15 Billion TWD | 29.896% |